# Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

> **NCT03832114** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Glomerulonephritis

## Interventions

- **DRUG:** LNP023

## Key facts

- **NCT ID:** NCT03832114
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-20
- **Primary completion:** 2021-04-23
- **Final completion:** 2021-04-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832114, "Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03832114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*